BLA 761161 · Chiesi Farmaceutici Spa
Elfabrio
Pegunigalsidase Alfa-Iwxj · Single-Use · Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme
NovelPriority reviewCDER novel approval, May 9, 2023: To treat confirmed Fabry disease
Last checked: Nov 20, 2026Latest source record: May 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 9, 2023
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
9
8 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat confirmed Fabry disease
Therapeutic areas: Cardiovascular and metabolic · Rare and genetic disease · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegunigalsidase Alfa" as an intervention, any sponsor and status, largest first.
- Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT03566017 · 97 participants · Start Sep 16, 2018 · Primary completion Jan 21, 2025
Drug: pegunigalsidase alfa · For: Fabry Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 30 sites in all
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal FunctionPivotal-lookingCompleted
ProtalixIndustry
NCT02795676 · 78 participants · Start Jun 2016 · Primary completion Oct 2021
Drug: PRX-102 (pegunigalsidase alfa); agalsidase beta · For: Fabry Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Orange, California · 29 sites in all
- Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 WeeksPivotal-lookingCompleted
ProtalixIndustry
NCT03180840 · 30 participants · Start Jul 10, 2017 · Primary completion Aug 1, 2020
Drug: Pegunigalsidase alfa · For: Fabry Disease
Sites: Birmingham, Alabama; Atlanta, Georgia; Iowa City, Iowa · 14 sites in all
- Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease PatientsPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT03614234 · 29 participants · Start Nov 13, 2018 · Primary completion Apr 13, 2026
Drug: pegunigalsidase alfa · For: Fabry Disease
Sites: Birmingham, Alabama; Atlanta, Georgia; Iowa City, Iowa · 14 sites in all
- Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)Pivotal-lookingCompleted
ProtalixIndustry
NCT03018730 · 22 participants · Start May 17, 2017 · Primary completion Dec 17, 2019
Drug: PRX-102 (pegunigalsidase alfa) · For: Fabry Disease
Sites: Parkville, Australia; Halifax, Canada; Prague, Czechia · 9 sites in all
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06328608 · 22 participants (planned) · Start Jul 29, 2025 · Primary completion Oct 2028
Drug: PRX-102 1 mg/kg every two weeks · For: Fabry Disease
Sites: Phoenix, Arizona; Atlanta, Georgia; Iowa City, Iowa · 12 sites in all
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT05710692 · 16 participants (planned) · Start Aug 1, 2023 · Primary completion Oct 2027
Drug: PRX-102 1 mg/kg every 2 weeks; PRX-102 2 mg/kg every 4 weeks · For: Fabry Disease
Sites: Chikushino-shi, Japan; Sendai, Japan; Nishihara, Japan · 10 sites in all
ProtalixIndustry
NCT01981720 · 15 participants · Start Jan 16, 2014 · Primary completion Aug 26, 2020
Drug: PRX-102 (pegunigalsidase alfa) · For: Fabry Disease
Sites: Gainesville, Florida; Iowa City, Iowa; Baltimore, Maryland · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Elfabrio (PEGunigalsidase Alfa-Iwxj)
2024 spending
$5.2M
Beneficiaries
15
141 claims
Per beneficiary
$345,331
$430.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $469,783 |
| 2024 | $5,179,970 |
Part B: Elfabrio (Pegunigalsidase Alfa-Iwxj) · HCPCS J2508
2024 spending
$4.2M
Beneficiaries
18
188 claims
Per beneficiary
$235,990
2024 ASP limit $223.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $4,247,817 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL, Goker-Alpan O, Wilcox WR, et al. · J Med Genet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4ߙweeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
Holida M, Linhart A, Pisani A, et al. · J Inherit Metab Dis 2025 · Clinical Trial, Phase III, Multicenter Study
- Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.
Holida M, Linhart A, Longo N, et al. · Orphanet J Rare Dis 2026 · Clinical Trial, Phase III, Multicenter Study
- Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
Schiffmann R, Goker-Alpan O, Holida M, et al. · J Inherit Metab Dis 2019 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with Fabry disease receiving enzyme replacement therapy: a systematic literature review.
Aguiar P, Bernat JA, Hughes D · Orphanet J Rare Dis 2026 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Chiesi Farmaceutici Spa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.